- Antares' flagship product, Otrexup, was approved in October 2013 and launched in the US in Q1 2014.
- Medac Pharma has filed for approval of a similar product, Rasuvo, with a PDUFA date of July 10, 2014.
- Antares filed a citizen’s petition to block FDA approval of Rasuvo. Mediation to occur on July 9, one day before PDUFA date for Rasuvo.
- ATRS CEO resigned in late June.
- Uncertainty has unnerved investors, creating a unique buying opportunity for a company with innovative drug delivery technology and valuable pipeline.